D. Boral Capital Maintains Buy on AVITA Medical, Lowers Price Target to $14
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and lowers the price target from $18 to $14.
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and lowers the price target from $18 to $14.